In this computational study, we identified eight best hits that could bind to the Akt-1 allosteric site, capable of treating NSCLC. The top best hits are valganciclovir, dasatinib, indacaterol, novobiocin, ezetimibe, delerozepam, pitavastatin and nebivolol. This evidence concerns the gene AKT1 and non-small cell lung carcinoma.